Adam Fleisher, MD, MAS
Eli Lilly & Co., Inc.
- 4 editions
- 5 talks
- 4 recordings
2023
- Symposium Biomarker changes associated with Clinical Treatment Effects in the Trail Blazer Trials with Donanemab
2017
- Symposium Imaging Predictors of Progression (Amyloid and Tau PET)
2014
- Workshop Biomarker Use to Assist in Diagnosis of Atypical MCI Presentations/ Imaging for identifying non-AD/ Imaging for Identifying Non-AD
- Public Forum Challenges in the Diagnosis of Early Alzheimer’s Disease
- Public Forum · Panelist The Role of Amyloid Imaging in the Diagnosis of Mild Cognitive Impairment: Current Research and Clinical Utility
2013
- Workshop The Role of Amyloid Imaging in Preclinical Alzheimer’s Treatment Trials
Degrees and affiliation are current where known; the program pages show affiliations as they were each year.